No Data
No Data
Roth MKM Maintains Moleculin Biotech(MBRX.US) With Buy Rating, Cuts Target Price to $40
Roth MKM analyst Jonathan Aschoff maintains $Moleculin Biotech(MBRX.US)$ with a buy rating, and adjusts the target price from $240 to $40.According to TipRanks data, the analyst has a success rate of
Maxim Group Maintains Moleculin Biotech(MBRX.US) With Buy Rating, Maintains Target Price $20
Maxim Group analyst Jason McCarthy maintains $Moleculin Biotech(MBRX.US)$ with a buy rating, and maintains the target price at $20.According to TipRanks data, the analyst has a success rate of 29.1% a
12 Health Care Stocks Moving In Friday's Pre-Market Session
GainersAinos (NASDAQ:AIMD) stock rose 54.8% to $1.27 during Friday's pre-market session. The market value of their outstanding shares is at $8.2 million. Longeveron (NASDAQ:LGVN) shares moved upwards
Express News | Moleculin Biotech Inc: Recruitment Increased to 22 Subjects and Crc's in All Subjects Evaluable for Efficacy (N=20) Was 45% in Study
Express News | Moleculin Biotech Inc: Annamycin Continues to Demonstrate No Cardiotoxicity
Express News | Moleculin Biotech Inc: Current Median Durability of Response (Mdor) of Crc's = 6 Months and Increasing (N=9) in Study
No Data